DESCRIPTION
A female infant was born at 27 +5 weeks of gestation through emergency caesarean section, performed because of an acute increase of a compressive thoracic malformation diagnosed at the 20th gestational week.
At birth, two enormous violaceous masses extending to thorax and superior limbs were observed (figure 1). The infant was immediately intubated and transfused because of severe anaemia. A compressive bandage on masses was performed to decrease the risk of bleeding. Angio-CT confirmed the presence of voluminous masses surrounding the thorax (figure 2).
A sclerosant approach and chemotherapy were not feasible due to the disease extent and location, and prematurity of the newborn. Prednisone therapy was started from the first day of life, but it was ineffective. Surgical removal was proposed, but the infant's family refused it.
Severe consumptive coagulopathy and large intralesional bleeding were corrected with transfusions of plasma, platelets and erythrocytes.
The patient died at 40 days of life due to acute bleeding. Autopsy confirmed the diagnosis of kaposiform haemangioendothelioma (KH).
KH is a vascular tumour usually present at birth or appearing in early infancy, which can resemble juvenile haemangioma in aspect and shows no tendency to spontaneous involution. It is often associated with Kasabach-Merritt phenomenon, a condition characterised by severe thrombocytopaenic coagulopathy resulting from platelet trapping within the vascular tumour, which can lead to life-threatening haemorrhage (mortality rate 20-30%). 1 2 Several therapeutic regimens, including corticosteroids, chemotherapy, radiotherapy and surgery have been reported, with variable rates of success. [1] [2] [3] Extreme prematurity reduces treatment chances, highly increasing the mortality rate.
Learning points
▸ Kaposiform haemangioendothelioma is a vascular tumour, usually present at birth, which shows no tendency to spontaneous involution and is often associated with Kasabach-Merritt phenomenon (KMP). 1 2 ▸ KMP is a condition characterised by severe thrombocytopaenic coagulopathy resulting from platelet trapping within the vascular tumour and is associated with high mortality rate (20-30%). 1 2 ▸ KMP optimal treatment has not yet been established; several therapeutic regimens, including corticosteroids, chemotherapy, radiotherapy and surgery have been reported. [1] [2] [3] Extreme prematurity reduces treatment chances, highly increasing the mortality rate. 
